Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib in Advanced Malignancies with MEK or Atypical BRAF Alterations
NCT04488003Phase 2Terminated
- Sponsor
- BioMed Valley Discoveries
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ulixertinib in solid tumor (advanced stage), colorectal cancer (CRC), sponsored by BioMed Valley Discoveries. Started Jan 2021; status: terminated.
02
Drugs
ulixertinib
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04488003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488003.